EFFICACY OF A FIXED DOSE OF OMALIZUMAB DURING MULTI-ALLERGEN ORAL-IMMUNOTHERAPY

被引：2
|
作者：
Sindher, S.
Kumar, D.
Purington, N.
Tupa, D.
Long, A.
Cao, S.
Woch, M.
Tan, T.
Skura, S.
Garcia-Lloret, M.
Chinthrajah, S.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.319
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P312
引用
收藏
页码：S50 / S51
页数：3
相关论文
共 50 条
  • [21] Three and a Half Years of Multi-Allergen Subcutaneous Immunotherapy Is Associated with a 50% Reduction in Asthma Symptom Scores
    Rael, Efren L.
    Ishmael, Faoud T.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB257 - AB257
  • [22] Transcriptome changes during peanut oral immunotherapy and omalizumab treatment
    Bjorkander, Sophia
    Merid, Simon Kebede
    Brodin, David
    Brandstrom, Josef
    Fagerstrom-Billai, Fredrik
    van Der Heiden, Marieke
    Konradsen, Jon R.
    Kabesch, Michael
    van Drunen, Cornelis M.
    Golebski, Korneliusz
    van der Zee, Anke H.
    Potocnik, Uros
    Vijverberg, Susanne J. H.
    Nopp, Anna
    Nilsson, Caroline
    Melen, Erik
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (01)
  • [23] Clinical efficacy of multi-nut very low dose oral immunotherapy
    Upton, J.
    Berenjy, A.
    Galper, A.
    Duan, L.
    Dorran, M.
    Wong, S.
    Ditlof, C.
    Li, C.
    Ben-Shoshan, M.
    Hoang, J.
    San Diego, K. E.
    Kothari, A.
    Hung, L.
    Moraes, T.
    Eiwegger, T.
    ALLERGY, 2023, 78 : 278 - 279
  • [24] Examination of IgG Subclasses and CD32b Receptor Expression on Leukocytes Associated with Multi-Allergen Immunotherapy
    Patel, Pooja
    Tversky, Jody
    MacGlashan, Donald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB132 - AB132
  • [25] Allergen immunotherapy for oral allergy syndrome: what is the evidence for efficacy?
    Treudler R.
    Klimek L.
    Allergo Journal International, 2019, 28 (2) : 50 - 56
  • [26] Eosinophilic esophagitis during sublingual and oral allergen immunotherapy
    Cafone, Joseph
    Capucilli, Peter
    Hill, David A.
    Spergel, Jonathan M.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 19 (04) : 350 - 357
  • [27] THE EFFICACY OF IMMUNOTHERAPY BY ORAL-ADMINISTRATION OF GRASS-POLLEN ALLERGEN
    URBANEK, R
    TREDE, N
    ENDE, K
    EUROPEAN JOURNAL OF PEDIATRICS, 1986, 144 (05) : 525 - 525
  • [28] Editorial: The safety, efficacy, and effectiveness of allergen-specific oral immunotherapy
    Lee, Alexandra
    Dekruyff, Rosemarie
    Ricciardi, Luisa
    FRONTIERS IN ALLERGY, 2024, 5
  • [29] Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study
    Sindher, Sayantani B.
    Kumar, Divya
    Cao, Shu
    Purington, Natasha
    Long, Andrew
    Sampath, Vanitha
    Zedeck, Stacey S.
    Woch, Margaret A.
    Garcia-Lloret, Maria
    Chinthrajah, Rebecca Sharon
    ALLERGY, 2022, 77 (06) : 1873 - 1884
  • [30] Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy (vol 16, 25, 2020)
    Langlois, Alexandra
    Lavergne, Marie-Helene
    Leroux, Helene
    Killer, Kerstin
    Azzano, Pauline
    Paradis, Louis
    Samaan, Kathryn
    Lacombe-Barrios, Jonathan
    Eiwegger, Thomas
    Upton, Julia
    Sussman, Gordon
    Poder, Thomas
    Masse, Benoit
    Roches, Anne Des
    Begin, Philippe
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2020, 16 (01):
12345